RemeGen Co. Ltd. Class H (HK:9995)
:9995
9995 Stock Chart & Stats
HK$115.20
-HK$0.38(-3.04%)
At close: 4:00 PM EST
HK$115.20
-HK$0.38(-3.04%)
Day’s Range― - ―
52-Week RangeHK$21.05 - HK$126.60
Previous CloseN/A
Volume1.38M
Average Volume (3M)6.34M
Market Cap
HK$83.77B
Enterprise ValueHK$83.02B
Total Cash (Recent Filing)HK$2.42B
Total Debt (Recent Filing)HK$2.20B
Price to Earnings (P/E)51.5
Beta1.48
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.47
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.84
Price to Sales (P/S)11.22
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$127.94Price Target Upside11.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.53
Revenue Forecast (FY)HK$6.73B
Bulls Say, Bears Say
Bulls Say
Revenue & Profitability RecoveryA sharp revenue rebound and return to positive net margins in 2025 indicate the business can scale commercial traction and convert sales into profit. This improvement supports sustainable operating leverage, funds R&D and commercialization, and reduces reliance on one-off accounting gains for future profitability.
High Gross Margins / Unit EconomicsConsistently elevated gross margins point to strong unit economics and pricing power for biologic therapies. Durable high margins bolster the firm's ability to invest in pipeline development, absorb clinical and regulatory costs, and support long-term profitability even if SG&A and R&D scale up.
Improving Capital Structure & ROERecovery in equity and a positive ROE indicate the company is converting assets into shareholder returns again. A moderate debt-to-equity ratio versus prior highs suggests the balance sheet is stabilizing, improving financial flexibility and lowering immediate refinancing pressure over the medium term.
Bears Say
Weak Cash Generation & Negative FCFOperating cash flow that lags reported earnings and persistently negative free cash flow reduce internal funding capacity. Over months, this elevates reliance on external financing, increasing dilution or refinancing risk and constraining the firm's ability to self-fund late-stage trials or commercial expansion.
Earnings Volatility / Milestone SensitivityHistoric swings between profit and loss indicate revenue and earnings depend on milestone payments, sporadic product launches, or episodic cost swings. Such volatility makes forecasting cash flows and funding needs harder, raising execution risk for multi-stage drug development and commercialization plans.
Past Reliance On Debt / Leverage RiskA history of meaningful debt increases during weak operating periods highlights vulnerability to funding stress. If cash conversion issues persist, the company may face constrained flexibility, higher interest or refinancing costs, and potential covenant or dilution risk over the coming months.
RemeGen Co. Ltd. Class H News
9995 FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$21.05 and its highest was HK$126.60 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$83.77B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Apr 29, 2026 which is in 23 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Mar 27, 2026. The company reported HK$2.471 earnings per share for the quarter, beating the consensus estimate of N/A by HK$2.471.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$2.471 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.264%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$127.94 (11.06% Upside)
HK$127.94 (11.06% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
495.23%
12-Months-Change
Fundamentals
Return on Equity
32.32%
Trailing 12-Months
Asset Growth
37.96%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
9995 Stock 12 Month Forecast
Average Price Target
HK$127.94
▲(11.06% Upside)
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---